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To the Editor:
An extensive literature points out that p53 plays a piv-
otal role in cell cycle, apoptosis, and cell senescence and
thus is crucial to a variety of physiological and patho-
logical processes. These data support the view that p53
could be considered a gene that affects human longevity.
In a previous letter (Bonafe` et al. 1999) we tested the
hypothesis that polymorphic variants of p53 have an
impact on human longevity, by comparing p53 codon
72 allelic and genotypic frequency distributions between
young people and centenarians. A nonsignificant differ-
ence emerged between the groups, and several expla-
nations were offered. Following the reply letter of Sun
et al. (in this issue), we would like to argue with some
of their comments and to provide new data regarding
centenarians from continental Italy and Sardinia. We
disagree with the conclusion of Sun et al. that a con-
sensus has been reached in the scientific community
about the lack of any important role of p53 codon 72
in cancer susceptibility. First, several articles (not quoted
by Sun et al.) still claim associations between codon 72
variants and lung cancer (Murata et al. 1998; Wang et
al. 1999) and hepatocellular carcinoma (Yu et al. 1999).
Second, in some cases, marginal differences regarding
allelic and genotypic distributions between cases and
controls have been found. In particular, Weston et al.
(1997) reported P values of .054 and .07 when codon
72 Arg/Pro alleles and genotypes, respectively, were com-
pared between Caucasian controls and patients affected
with breast cancer. These authors failed to detect any
differences in Mexican Americans or African Americans
by use of case-control comparisons. These results cannot
be considered conclusive evidence against an association,
because the sample sizes analyzed were small (65 pa-
tients vs. 117 controls for Caucasians; 18 cases vs. 38
controls for Hispanics; 16 cases vs. 30 controls for Af-
rican Americans). We doubt that samples of such size
can be considered representative of Caucasian,Mexican,
or African populations. Third, in several studies, im-
portant interactions among the codon 72 polymorphism
and age (Murata et al. 1998), sex (Wang et al. 1999),
environment, and other gene variants (Yu et al. 1999)
have been reported. We tried to model this complex sce-
nario (Bonafe` et al. 1999), and methodologically new
possible approaches have been proposed (De Benedictis
et al. 1998; Yashin et al. 1998, 1999). Using experi-
mental data on ApoB alleles in Italian subjects of dif-
ferent ages, including centenarians, we showed that the
genotype relative risk (RR) of death can change with
age, thus giving rise to unexpected nonmonotonic age-
related trajectories. Comparable approaches to unrav-
eling the possible effect of antagonistic pleiotropy on
age-related genotypic changes during aging have been
proposed (Toupance et al. 1997), with data on ACE
genotypes in French centenarians. On the whole, un-
expected results can be obtained by studying the genetics
of centenarians. An understanding of the biological
meaning of allele and genotype frequency distributions
of centenarians requires an integrated approach that
combines genetic and demographic data (Yashin et al.
1998, 1999). Calculations such as those proposed by
Sun et al. may be inadequate, given that changes, with
age, of RR for cancer (and death) have been reported
for p53 variants (Weston et al. 1997). We disagree with
the assumption that an RR of dying of 1.5–2 can be
attributed to people carrying particular p53 codon 72
alleles. Sun et al. first strongly argue in favor of the
hypothesis that codon 72 alleles are neutral, but then
they assume this specific RR for Pro-allele carriers (“even
though we do not agree there is a good evidence for an
association between Codon 72 and cancer susceptibility,
let us assume”). Because the power analysis performed
by Sun et al. is based on this arbitrary assumption, their
conclusions do not invalidate our interpretation of the
data that we obtained in our study on the frequency of
p53 variants in centenarians. We disagree with the con-
clusion of Sun et al. that the Pro/Arg sequence difference
is functionally neutral. Recently, it has been demon-
strated that codon 72 alleles differ biochemically and
biologically in their ability to bind components of the
transcriptional machinery, to activate transcription, to
induce apoptosis, and to repress the transformation of
primary cells (Thomas et al. 1999). We agree that hap-
lotypes of codon 72 (BstUI, exon 4), MspI site (intron
6), and 16-bp insertion/deletion (intron 3) can help to
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Table 1
Allelic and Genotypic Frequencies of the p53 Codon 72
Polymorphism in Continental Italy
NO. (%) OF
Controls ( )n = 611 Centenarians ( )n = 394
p53 Allele:a
Pro 332 (27.8) 231 (28.3)
Arg 890 (72.2) 557 (71.7)
p53 Genotype:b
Pro/Pro 49 (8.0) 29 (7.4)
Pro/Arg 234 (38.3) 173 (44.0)
Arg/Arg 328 (53.7) 192 (48.6)
NOTE.—Hardy-Weinberg equilibrium (HWE) of p53 geno-
types was assessed by exact tests. Both groups were in HWE:
younger controls, ; and centenarians, . x2 Tests forP = .53 P = .23
comparison of allelic and genotypic distributions were performed
by use of Monte Carlo algorithms implemented by means of the
Statistical Product and Service Solutions (SPSS) package.
a , df 1, .2x = 1.09 P = .29
b , df 2, .2x = 3.13 P = .20
detect associations in case-control studies regarding p53
polymorphisms and cancer susceptibility, but we disa-
gree that the data available in the literature are conclu-
sive. Indeed, in the three molecular epidemiology studies
(Sjalander et al. 1996; Wang-Gohrke et al. 1998;Weston
1998 et al.) quoted by Sun et al. as proof of the in-
volvement of a peculiar p53 haplotype in human cancer
(breast), some inconsistencies should suggest amore cau-
tious approach in the interpretation of the results. In
particular, in the first study (Sjalander et al. 1996), the
control sample was composed of a heterogeneous group
of placental samples and blood samples from sex- and
age-matched women. Moreover, a deficiency of hetero-
zygotes and a slight deviation from Hardy-Weinberg
equilibrium were found in the control group. These facts
affect the reliability of p53 haplotype estimations. As
stated by Sjalander et al., these data on genotypic com-
binations could “provide some idea” but did not offer
definitive results concerning the role of a particular
three-locus p53 haplotype in cancer susceptibility. In the
second study (Wang-Gohrke et al. 1997), the results ap-
pear to be quite blunt (the BstUI–16-bp–MspI haplotype
1-2-1 increases in cases from .108 to .137, the 2-2-1
from 0 to .012) and apparently contradictory. Indeed, a
significant difference between cases and controls, with
regard to the 16-bp–MspI 2-1 haplotype, appears to be
present when a three-locus analysis is performed, but the
same difference is not confirmed when a two-locus anal-
ysis is used. Thus, the biological role of p53 haplotypes
in cancer susceptibility deserves further investigation. In
analyses performed by Weston et al. (1997) the OR
(odds ratio) estimates on “true” extended haplotypes are
based on comparisons of 18 cases versus 38 controls
and of 16 cases versus 30 controls. We think that ORs
resulting from such small studies cannot provide reliable
estimates of the RR of death for people carrying partic-
ular genotypes or haplotypes in Italian or other popu-
lations. Moreover, these three studies refer only to the
risk for breast cancer. In our letter (Bonafe` et al. 1999)
the difference between the allele/genotype distributions
of 176 centenarians and 204 controls was not statisti-
cally significant. However, Sun et al. made a number of
speculations on the small differences between allele and
genotype frequencies of young people versus centenar-
ians. They claimed that these figures were consistentwith
their a priori hypothesis of an RR of 1.5–2 for death,
for Pro/Pro (8.8% in controls vs. 6.8% in centenarians),
Pro carriers (53.9% in controls vs. 50.6% in centenar-
ians), and Pro alleles (31.4% in controls vs. 28.7% in
centenarians). In association studies, it is not unreason-
able to predict that such small, nonsignificant differences
can vanish or reverse as the sample size increases orwhen
replications are performed. Thus, we thought that the
best approach was to provide experimental data by stud-
ying more subjects, either centenarians or controls, and
to replicate the study in another population. Unfortu-
nately, we were unable to study the 4,091 centenarians
suggested by Sun et al. The reason was quite simple.
According to the data of several laboratories, including
our own, the prevalence of centenarians is ∼80/1 million
inhabitants in developed countries—such as Italy, Den-
mark, Finland, and Sweden, among others—where re-
liable age validation is possible. The actual number of
centenarians living in Italy (which has ∼57 million in-
habitants) is thought to be ∼4,500–5,000 (Capurso et
al. 1997), considering the rapid increase of the oldest
old in the population. We are not aware of anybody in
the world capable of performing studies on 4,000 cen-
tenarians from an ethnically and/or geographically ho-
mogeneous population. This difficulty would be even
higher if only a small minority of centenarians were rel-
atively healthy. In table 1, new data are shown on allele
and genotype frequency of p53 codon 72 polymor-
phisms in a total of 1,005 people. An additional 218
centenarians and 407 controls have been included with
respect to the data reported elsewhere (Bonafe` et al.
1999). The data reported here confirm, in a larger sam-
ple, that no significant difference is detectable between
centenarians and young controls.
With the various possible biases inherent in associa-
tion studies, replications of studies in other ethnically
and/or geographically different populations can help us
to better understand the obtained results. Thus, we
thought it worthwhile to study the allelic and genotypic
distributions of p53 codon 72 in Sardinian centenarians
and appropriate younger controls (Deiana et al., in
press). The data regarding Sardinian centenarians are
reported in table 2. In Sardinian controls, the frequencies
of p53 Pro and Arg alleles are 20.1% and 79.8%, re-
spectively. This frequency is significantly different from
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Table 2
Allelic and Genotypic Frequencies of the p53 Codon 72
Polymorphism in Sardinia
NO. (%) OF
Controls ( )n = 92 Centenarians ( )n = 110
p53 Allele:a
Pro 37 (20.1) 51 (23.2)
Arg 147 (79.9) 169 (76.8)
p53 Genotype:b
Pro/Pro 4 (4.4) 4 (3.6)
Pro/Arg 29 (31.5) 43 (39.1)
Arg/Arg 59 (64.1) 63 (57.3)
NOTE.—Hardy-Weinberg equilibrium (HWE) of p53 geno-
types was assessed by exact tests. Both groups were in HWE:
younger controls, ; and centenarians, . x2 tests forP = .75 P = .43
comparison of allelic and genotypic distributions were per-
formed by use of Monte Carlo algorithms implemented by
means of the Statistical Product and Service Solutions (SPSS)
package.
a , df 1, .2x = 0.55 P = .45
b , df 2, .2x = 1.25 P = .53
that found in controls from continental Italy ( 2x =
, df 1, ). Despite this ethnic difference,4.11 P = .042
again, no statistically significant difference was found
between Sardinian centenarians and Sardinian controls.
The difference between the two groups, with regard to
the frequency of the Pro 72 allele, was ∼3% in favor of
centenarians. Moreover, the Pro 72 allele carriers were
slightly increased in Sardinian centenarians (42.7% in
centenarians vs. 35.9% in controls), and this trend is
similar to that found in centenarians from continental
Italy (table 1). We consider these data on Sardinian cen-
tenarians to be additional evidence that both p53 codon
72 alleles are equally compatible with extreme longevity.
In conclusion, we consider the study of the genetics
of extreme longevity to be worthwhile, even if some
important effects can be missed by the limited size of
the samples that can reasonably be recruited. These lim-
itations are frequently encountered even in other types
of association studies, including cancer studies (Weston
et al. 1997). In any case, the study of p53 haplotypes
related to cancer susceptibility can be of considerable
help in disentangling this difficult topic. We are follow-
ing this approach, and we hope that new data will
emerge soon.
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